Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

October 19, 2021

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2023

Conditions
Relapsing Multiple SclerosisMultiple Sclerosis
Interventions
DIAGNOSTIC_TEST

Cerebrospinal and Blood Serum Semaphorin 4A Levels

Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.

Trial Locations (1)

97225

Providence St. Vincent Medical Center, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Milton S. Hershey Medical Center

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Providence Health & Services

OTHER